The Real Cost of Medication Non-Adherence and How to Calculate It for Your Portfolio

Most commercial teams in the pharmaceutical industry know that poor adherence is a problem. Fewer have sat down and calculated what it actually costs their specific products, in real numbers, right now. That calculation is worth doing, and this article is designed to help you do it.

The global figures are striking on their own. According to estimates from a study by Capgemini Consulting and HealthPrize Technologies, pharmaceutical companies lose around $637 billion worldwide every year due to poor adherence, with US losses alone reaching $250 billion annually. Revenue losses equivalent to 50 to 60 percent of total annual US drug sales are attributed to patients not filling their prescriptions or not taking their medication as prescribed. And yet, when commercial and brand teams allocate budgets at mid-year, investment in patient support is often the first line item to be cut rather than protected.

The reason for this pattern is not bad faith or ignorance. It is a measurement problem. The revenue that poor adherence destroys is invisible in most commercial reporting systems because it never materializes in the first place. You cannot see revenue that was never generated. And budget decisions are made on the basis of what you can see.

This article aims to make that invisible number visible for your portfolio, so that the conversation about investing in patient support can rest on the same commercial logic that drives every other budget decision.

What non-adherence really costs a brand

Before we get to the calculation framework, it is worth defining precisely what non-adherence means in commercial terms, because the industry uses several terms interchangeably that describe different problems with different financial consequences.

Adherence, sometimes also called compliance, refers to whether patients take their medication correctly in terms of dose, timing, and instructions during the course of therapy. Patients who are on therapy but regularly take their medication at the wrong time or in the wrong dose are not adherent, even if they appear as active users in prescription data.

Persistence refers to how long patients stay on therapy before discontinuing it altogether. Patients who stop treatment after three months despite having been prescribed a twelve-month course are not persistent. This is usually the dimension with the greatest commercial impact, because it determines the total number of prescriptions patients generate over the course of their treatment.

Primary non-adherence refers to patients who receive a prescription but never fill it in the first place. This is a significant problem for specialty medications, where prescription abandonment rates can reach 30 to 40 percent, meaning that between a third and almost half of all prescriptions written for high-value therapies are never filled.

Each of these dimensions contributes to the overall revenue gap in a different way, and interventions that address one may not solve the others. A commercial team that measures only refill rates, for example, does not see the full picture of what non-adherence is costing its brand.

The five financial consequences of non-adherence

Non-adherence affects a brand's commercial performance through five distinct mechanisms, and understanding all five is necessary to build a complete picture of the cost.

The first and most direct is lost prescription volume. Every missed dose, every refill not collected, and every prescription not filled represents direct revenue that was never generated. For a product with a monthly prescription value of €3,000 and a one-year persistence rate of 50 percent, half of all patients have stopped generating revenue within twelve months of their first prescription.

The second is reduced patient lifetime value. The commercial value of patients is determined not only by the cost of a single prescription but by the total number of prescriptions they generate over the course of their treatment. A patient who stays on therapy for 24 months is worth roughly twice as much as one who discontinues after twelve months. Interventions that extend persistence even modestly, by an average of six to eight weeks across a population, can generate substantial aggregate revenue at scale.

The third is the erosion of prescriber confidence. Doctors who watch patients struggle with side effects, express confusion about their therapy, or discontinue treatment quickly form opinions about a product's real-world performance that differ from its clinical trial profile. Those opinions influence prescribing behavior. A product that shows poor real-world persistence, even when its clinical trial data is strong, will lose prescriber confidence in a way that is hard to win back. This is one of the most underestimated long-term commercial consequences of non-adherence.

The fourth is the impact on health technology assessment and market access. As we discussed in our article on the EU Joint Clinical Assessment, national Health Technology Assessment bodies across Europe are increasingly asking for evidence of real-world effectiveness alongside clinical trial data. A product whose real-world persistence data shows a substantial early discontinuation rate makes a weaker case for its reimbursement value than one whose patients stay on therapy and report positive treatment experiences. Non-adherence does not just cost revenue today. It weakens the evidence base that will determine pricing and access decisions tomorrow.

The fifth is vulnerability to reputational damage and loss of market share. In highly competitive therapeutic areas, patients who discontinue a product often switch to a competitor rather than resuming treatment. Non-adherence that goes unaddressed becomes a competitive weakness that drives churn and transfers revenue directly to competing brands.

A practical framework for calculating the cost of non-adherence in your portfolio

The following framework is designed to give commercial teams a working estimate of the revenue impact of non-adherence for a specific product, using data that most brand teams already have access to or can reasonably estimate.

The calculation has four steps.

The first step is to establish your current adherence baseline. Using pharmacy refill data, medication possession ratio (MPR) data, or proportion of days covered (PDC) data from your market access or outcomes research team, determine the current one-year persistence rate for your product. Industry benchmarks suggest that roughly 50 percent of patients with chronic conditions are still on therapy after twelve months, but rates vary considerably by therapeutic area. Specialty biologics in immunology and oncology tend to show higher persistence than oral medications in cardiology or metabolic diseases, but even within specialty areas there is considerable variation.

The second step is to calculate your total addressable patient population and its aggregate annual prescription value. Take the number of active patients on your product at any given point in time, multiply by the average annual prescription revenue per patient, and this gives you your current revenue base. Now apply your persistence rate. If 40 percent of patients discontinue within twelve months and your average patient generates annual prescription revenue of €24,000, you are losing €9,600 per discontinuing patient. Multiply across your active patient population to get the aggregate annual revenue gap.

The third step is to model the revenue impact of a moderate improvement in adherence. Research by Capgemini and HealthPrize found that increasing adherence rates by just ten percentage points generates a $41 billion revenue opportunity for manufacturers in the US alone. At the level of an individual product, ZS Associates' analysis of adherence and revenue found that products with the lowest medication possession ratio in their respective markets would increase their dispensed volumes and the associated revenue by an average of 10 percent if they improved compliance to the market average. Apply a conservative improvement scenario of 5 to 10 percent to your persistence rate and calculate the total revenue that would be recovered as a result.

The fourth step is to factor in the cumulative effects. Patients who stay on therapy six months longer than average do not just generate six additional months of prescription revenue. They are also more likely to generate real-world evidence data, more likely to become a positive reference for their prescribing doctor, and less likely to switch to a competitor. These downstream effects are harder to quantify precisely, but they can be estimated by looking at the relationship between persistence duration and repeat prescribing behavior in your existing patient data.

The overall figure that emerges from this four-step calculation is almost always larger than commercial teams expect, because most planning models focus on acquiring new patients rather than retaining existing ones and therefore systematically underestimate the revenue that non-adherence is quietly eroding within the existing patient base.

Where revenue is lost and why the first ninety days matter most

One of the most consistent findings in adherence research is that the risk of discontinuation is not evenly distributed across a patient's treatment journey. It is heavily concentrated in the first ninety days after the first prescription.

This is the period in which patients are least certain whether the therapy is working, most likely to experience unexpected side effects without adequate support, and most likely to experience the sense of abandonment that XO Life's research has identified as one of the primary drivers of early discontinuation, with 60 percent of patients reporting that they feel left alone during their treatment.

For commercial teams, this concentration of discontinuation risk has an important practical implication. Interventions focused on the first ninety days deliver disproportionate commercial returns compared with those focused on the broader treatment journey, because this is where the greatest volume of patients is lost and where timely, personalized support has the greatest opportunity to change behavior.

A patient support program that successfully extends average persistence from ninety days to six months does not just recover revenue for those three additional months. It changes the entire trajectory of a patient's treatment journey and significantly increases the likelihood that the patient reaches twelve months and beyond, where persistence rates begin to stabilize.

What investment in patient support actually costs compared with what it delivers

The ROI case for investing in patient support is stronger than most internal planning models reflect, and the reason it is so often underestimated is the same measurement problem that makes the cost of non-adherence invisible: the returns are spread over time and across multiple functions in a way that cannot always be cleanly attributed to a single budget line.

A comprehensive systematic review of 64 studies found that 66 percent of adherence-focused patient support program interventions reported statistically significant improvements in adherence outcomes. An analysis of the HUMIRA Complete patient support program, which followed patients over 36 months, found that 69 percent of program participants were still on therapy after twelve months, compared with 55 percent of the control group, with the difference persisting throughout the entire 36-month follow-up period. For a product with a monthly prescription value of €2,000, a 14-percentage-point improvement in twelve-month persistence across a population of 10,000 patients represents €33.6 million in additional annual revenue, even before accounting for the cumulative effects of extended persistence and improved prescriber confidence.

Research published in PharmExec on the ROI of specialty pharmacy patient support programs found that programs achieving medication possession ratios 7 to 10 percent higher than retail channels, and twelve-month persistence of 50 to 60 percent compared with 30 to 40 percent in unsupported channels, generated returns that substantially exceeded the cost of program delivery. Broader analyses suggest that leading patient support programs achieve an ROI of 15 to 40 percent through reduced prescription abandonment, longer treatment duration, and market share protection.

The investment required for meaningful patient support has also changed considerably with the emergence of integrated health platforms. The cost of building and maintaining a standalone branded patient support app, which we discussed in detail in an earlier article in this series, runs to €500,000 to €2 million for development alone, before ongoing maintenance, content production, and regulatory compliance costs. An integrated platform model that delivers structured, personalized patient support within a health ecosystem that patients already use reduces that investment considerably while generating higher engagement, better persistence data, and more credible real-world evidence as a by-product.

The calculation your budget meeting needs

To boil this down to a number that is useful in a mid-year budget conversation, here is the simplest version of the adherence revenue calculation, which most commercial teams can run with the data they already have.

Take your current number of active patients. Multiply by the average annual prescription revenue per patient. Multiply by your current non-persistence rate, that is, the proportion of patients who discontinue within twelve months. That is your current annual revenue gap from non-adherence. Now calculate what a 10 percent improvement in persistence would generate. That is your revenue opportunity from investing in patient support, against which any investment in patient engagement infrastructure should be measured.

For a product with 20,000 active patients, average annual prescription revenue of €18,000 per patient, and a twelve-month discontinuation rate of 45 percent, the current annual revenue gap is €162 million. A 10 percent improvement in persistence recovers €16.2 million a year. A patient support program that costs €2 million a year and delivers that improvement has an ROI of more than 700 percent, even before accounting for the downstream effects on prescriber confidence, real-world evidence quality, and the competitive protection of market share.

These figures will vary considerably by product, therapeutic area, and patient population. But the structure of the calculation is consistent, and the result almost always produces a number that is considerably larger than the budget allocated to addressing it.

What commercial teams should be asking now

The mid-year budget review is the right moment to ask three questions that most commercial teams are not yet asking systematically.

The first is: What is our current twelve-month persistence rate, and how does it compare with the market average for our therapeutic area? If your product's persistence is below the market average, that gap represents both a patient experience problem and a recoverable revenue opportunity that deserves a line in the commercial plan.

The second is: Where in the treatment journey are patients most likely to discontinue, and what are the main reasons? The answer to this question determines which type of intervention will have the greatest impact. If patients discontinue in the first ninety days because of unmanaged side effects, the investment priority is structured side effect support and fast clinical access. If they discontinue because of complexity or uncertainty about whether the therapy is working, the priority is education and progress tracking. Getting the diagnosis right before allocating budget matters as much in commercial strategy as it does in clinical medicine.

The third is: What would a 10 percent improvement in persistence be worth for this brand, and is that number larger than the budget we currently allocate to patient support? For most brands, the answer to the second part of that question is yes, often substantially so, and that gap between the value of the opportunity and the investment being made to capture it is the commercial case for patient support that belongs in every mid-year budget review.

Non-adherence is not a patient behavior problem that sits outside the commercial plan. It is a revenue problem that sits at its very center. The brands that start measuring it that way and allocating resources accordingly are the ones that will look back in three years and wonder why they waited so long.

Discover how brite supports pharmaceutical companies in building patient relationships that protect and grow brand revenue at britehealth.com/en-de/partner/pharma